CTOR
Citius Oncology, Inc.
Healthcare — Drug Manufacturers - Specialty & Generic
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
None
1 analysts
$0.98
$-0.03 (-2.97%)
Target:
$4.00
(308.2%)
Price History
52-Week Range
Sign in to add CTOR to a watchlist or set price alerts.
Fundamentals
| Market Cap | $55.07M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.50 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -119.90% |
| Debt/Equity | 10.78 |
| Recommendation | None |
| Analyst Target | $4.00 |
| Analysts | 1 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 33.0 |
| Beta | 3.48 |
| SMA 20 | $0.63 |
| SMA 40 | $0.66 |
| 52-Week High | $2.31 |
| 52-Week Low | $0.49 |
| 50-Day Avg | $0.69 |
| 200-Day Avg | $1.00 |
| Avg Volume | 68.6K |
| Volume | 38.1K |
Performance Analysis
NEUTRALCTOR presents a mixed picture with both positive and negative indicators.
~
Trading at 27% of its 52-week range.
~
RSI at 33.0 is in neutral territory.
~
Wall Street consensus is "none" from 1 analysts.
+
Average analyst target of $4.00 implies 308.2% upside.
Recent News
Loading news...
Last updated: Aug 01, 2026 04:13 UTC
Back to Screener Export Report